Vivekananda Budamagunta, PhD.

Citée par

	Toutes	Depuis 2020
Citations	756	754
indice h	12	12
indice i10	12	12

240

120

180

20202021202220232024202525 99 157 185 240 46

Accès public

Tout afficher

11 articles

1 article

disponibles

non disponibles

Sur la base des exigences liées au financement

Coauteurs

Daohong ZhouUniversity of Texas Health Science Center at San AntonioAdresse e-mail validée de uthscsa.edu
Guangrong ZhengProfessor, University of FloridaAdresse e-mail validée de cop.ufl.edu
Sajid KhanAssistant Professor at the University of Texas Health Science Center San AntonioAdresse e-mail validée de uthscsa.edu
XUAN ZHANGProfessor, Shanghai Institute of Materia Medica, CASAdresse e-mail validée de simm.ac.cn
Dinesh ThummuriUniversity of FloridaAdresse e-mail validée de cop.ufl.edu
Peiyi ZhangChemist, University of FloridaAdresse e-mail validée de cop.ufl.edu
Yonghan HeProfessor, Kunming Institute of Zoology, Chinese Academy of SciencesAdresse e-mail validée de mail.kiz.ac.cn
Dongwen Lv (Lyu)Department of Biochem & Structural Biology, GCCRI, UT Health San AntonioAdresse e-mail validée de uthscsa.edu
Yaxia YuanUniversity of Texas Health Science Center at San AntonioAdresse e-mail validée de uthscsa.edu
Nan HuaUniversity of FloridaAdresse e-mail validée de ufl.edu
Raphael KochUniversitätsmedizin GöttingenAdresse e-mail validée de med.uni-goettingen.de
Jennifer Hartt ElisseeffJohns HopkinsAdresse e-mail validée de jhu.edu
Xingui LiuUniversity of FloridaAdresse e-mail validée de ufl.edu
Maria AlmeidaProfessor of Medicine, University of Arkansas for Medical SciencesAdresse e-mail validée de uams.edu
Ha-Neui KimAssistant Professor of Endocrinology, University of Arkansas for Medical ScienceAdresse e-mail validée de uams.edu
Jing PeiPh.D., Pharmaceutical Sciences, University of FloridaAdresse e-mail validée de ufl.edu
Patrick UnderwoodUniversity of FloridaAdresse e-mail validée de surgery.ufl.edu

Suivre

Vivekananda Budamagunta, PhD.

Scientist, Nautilus Biotechnology

Adresse e-mail validée de nautilus.bio

Aging Neuroscience Proteomics Transcriptomics Senolytics


Titre Trier par citations Trier par année Trier par titre	Citée par Citée par	Année
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity Y He, X Zhang, J Chang, HN Kim, P Zhang, Y Wang, S Khan, X Liu, ... Nature communications 11 (1), 1996, 2020	225	2020
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas Y He, R Koch, V Budamagunta, P Zhang, X Zhang, S Khan, D Thummuri, ... Journal of hematology & oncology 13, 1-13, 2020	101	2020
Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity Y He, W Li, D Lv, X Zhang, X Zhang, YT Ortiz, V Budamagunta, J Campisi, ... Aging cell 19 (3), e13117, 2020	92	2020
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines X Zhang, Y He, P Zhang, V Budamagunta, D Lv, D Thummuri, Y Yang, ... European journal of medicinal chemistry 199, 112397, 2020	54	2020
Cellular senescence in lymphoid organs and immunosenescence V Budamagunta, TC Foster, D Zhou Aging (Albany NY) 13 (15), 19920, 2021	51	2021
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X_L–Specific Degrader DT2216 D Thummuri, S Khan, PW Underwood, P Zhang, J Wiegand, X Zhang, ... Molecular cancer therapeutics 21 (1), 184-192, 2022	45	2022
Senescence-associated hyper-activation to inflammatory stimuli in vitro V Budamagunta, S Manohar-Sindhu, Y Yang, Y He, DO Traktuev, ... Aging (Albany NY) 13 (15), 19088, 2021	41	2021
BCL-X_L PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS^G12C-mutated cancers S Khan, J Wiegand, P Zhang, W Hu, D Thummuri, V Budamagunta, N Hua, ... Journal of Hematology & Oncology 15 (1), 23, 2022	39	2022
Nanovesicle and extracellular polymeric substance synthesis from the remediation of heavy metal ions from soil V Budamagunta, N Shameem, S Irusappan, JA Parray, M Thomas, ... Environmental Research 219, 114997, 2023	31	2023
Effect of peripheral cellular senescence on brain aging and cognitive decline V Budamagunta, A Kumar, A Rani, L Bean, S Manohar‐Sindhu, Y Yang, ... Aging Cell 22 (5), e13817, 2023	28	2023
Co-targeting BCL-X_L and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice S Khan, P Kellish, N Connis, D Thummuri, J Wiegand, P Zhang, X Zhang, ... Cell Death Discovery 9 (1), 1, 2023	23	2023
Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies S Khan, V Budamagunta, D Zhou Advances in Cancer Research 159, 145-184, 2023	12	2023
DT2216, a BCL-XL proteolysis targeting chimera (PROTAC), is a potent anti T-cell lymphoma agent that does not induce significant thrombocytopenia Y He, R Koch, V Budamagunta, D Lv, S Khan, X Zhang, JS Wiegand, ... Blood 134, 303, 2019	5	2019
Senolytic treatment alleviates doxorubicin‐induced chemobrain V Budamagunta, A Kumar, A Rani, S Manohar Sindhu, Y Yang, D Zhou, ... Aging cell 23 (2), e14037, 2024	4	2024
Failure of senolytic treatment to prevent cognitive decline in a female rodent model of aging A Rani, L Bean, V Budamagunta, A Kumar, TC Foster Frontiers in Aging Neuroscience 16, 1384554, 2024	3	2024
A BCL-X_L PROTAC degrader DT2216 synergizes with KRAS^G12C inhibitors for effectively treating KRAS^G12C-mutated cancers S Khan, J Wiegand, P Zhang, W Hu, D Thummuri, V Budamagunta, N Hua, ... Cancer Research 82 (12_Supplement), 5313-5313, 2022	2	2022
The Uncharted Avenues of Cellular Senescence V Budamagunta University of Florida, 2022		2022

Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.

Articles 1–17

Nombre de citations par an

Citations en double

Citations fusionnées

Ajouter les coauteursCoauteurs

Suivre

Citée par

Coauteurs